A. Romero-Lorca

发表

miR-7, miR-10a and miR-143 Expression May Predict Response to Bevacizumab Plus Chemotherapy in Patients with Metastatic Colorectal Cancer

A. Fernández-Santander, A. Romero-Lorca, A. Novillo, 2021, Pharmacogenomics and personalized medicine.

Somatic Mutations in HER2 and Implications for Current Treatment Paradigms in HER2-Positive Breast Cancer

A. Fernández-Santander, A. Romero-Lorca, A. Novillo, 2020, Journal of oncology.

North African genetic variation of cytochrome and sulfotransferase genes

A. Fernández-Santander, A. Romero-Lorca, A. Novillo, 2015 .

Impacts of the Glucuronidase Genotypes UGT1A4, UGT2B7, UGT2B15 and UGT2B17 on Tamoxifen Metabolism in Breast Cancer Patients

F. Bandrés, A. Fernández-Santander, A. Romero-Lorca, 2015, PloS one.

Tamoxifen Therapy in Breast Cancer: Do Apolipoprotein E Genotype and Menopausal State Affect Plasma Lipid Changes Induced by the Drug?

A. Tejerina, F. Bandrés, A. Romero-Lorca, 2013, The International journal of biological markers.

Differential expression of PMCA2 mRNA isoforms in a cohort of Spanish patients with breast tumor types

A. Armesilla, A. Fernández-Santander, A. Romero-Lorca, 2018, Oncology letters.

Role of Chromodomain-Helicase-DNA-Binding Protein 4 (CHD4) in Breast Cancer

Pablo Gómez-del Arco, A. Fernández-Santander, A. Romero-Lorca, 2021, Frontiers in Oncology.

UDP-glucuronosyltransferase genetic variation in North African populations: a comparison with African and European data

P. Moral, A. Fernández-Santander, H. Chaabani, 2018, Annals of human biology.

Pharmacogenetics of ugt genes in North African populations

A. Fernández-Santander, A. Romero-Lorca, A. Novillo, 2018, The Pharmacogenomics Journal.

Efficacy of bevacizumab-containing chemotherapy in metastatic colorectal cancer and CXCL5 expression: Six case reports

A. Fernández-Santander, A. Romero-Lorca, A. Novillo, 2020, World journal of gastroenterology.

Genetic diversity of CYP3A4 and CYP3A5 polymorphisms in North African populations from Morocco and Tunisia

E. Esteban, N. Harich, A. Fernández-Santander, 2015, The International journal of biological markers.

FGFR1 Amplification and Response to Neoadjuvant Anti-HER2 Treatment in Early HER2-Positive Breast Cancer

A. Fernández-Santander, A. Romero-Lorca, A. Novillo, 2022, Pharmaceutics.

HER2 and BARD1 Polymorphisms in Early HER2-Positive Breast Cancer Patients: Relationship with Response to Neoadjuvant Anti-HER2 Treatment

A. Fernández-Santander, A. Romero-Lorca, A. Novillo, 2023, Cancers.

Relationship between Genotypes Sult1a2 and Cyp2d6 and Tamoxifen Metabolism in Breast Cancer Patients

A. Tejerina, F. Bandrés, A. Fernández-Santander, 2013, PloS one.

Genetic Variants of ANGPT1, CD39, FGF2 and MMP9 Linked to Clinical Outcome of Bevacizumab Plus Chemotherapy for Metastatic Colorectal Cancer

A. Fernández-Santander, A. Romero-Lorca, A. Novillo, 2021, International journal of molecular sciences.

Cytochrome and sulfotransferase gene variation in north African populations.

P. Moral, N. Harich, A. Fernández-Santander, 2016, Pharmacogenomics.

Tamoxifen metabolism in breast cancer treatment: Taking the focus off the CYP2D6 gene

A. Fernández-Santander, A. Romero-Lorca, A. Novillo, 2016, The Pharmacogenomics Journal.